Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.

Yu L, Li C, Guo D, Cui S

Open source

DOI
10.3389/fimmu.2026.1932951
Published
2026
Container
Frontiers in immunology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1932951,
  title = {Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.},
  author = {Yu L and Li C and Guo D and Cui S},
  year = {2026},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2026.1932951},
  url = {https://doi.org/10.3389/fimmu.2026.1932951}
}

RIS

TY  - JOUR
TI  - Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.
AU  - Yu L
AU  - Li C
AU  - Guo D
AU  - Cui S
PY  - 2026
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2026.1932951
UR  - https://doi.org/10.3389/fimmu.2026.1932951
ER  - 

APA

L, Y., C, L., D, G., & S, C. (2026). Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1932951

Source records